Foundayo (orforglipron) is an FDA-approved daily oral GLP-1 receptor agonist from Eli Lilly, launched in April 2026 for chronic read more weight management in adults with obesity or overweight. As a non-peptide small molecule, it works without food/water restriction… Read More